Cybin Inc. filings document Helus Pharma's status as a foreign issuer reporting current events through Form 6-K materials and related exhibits. The filings include company news releases covering the HLP003 and HLP004 clinical programs, regulatory designations, clinical research collaborations, scientific advisory matters, and management changes.
The company's regulatory record also covers capital-structure disclosure, shareholder voting matters, governance matters, clinical or regulatory disclosures, operating and financial results, and risk-oriented cautionary statements associated with its clinical-stage pharmaceutical business.
Cybin Inc. director Eric H. L. So received a grant of 248,000 restricted stock units on September 30, 2026, with immediate vesting. Each RSU represents a right to receive one common share. He reported 4,713,014 common shares held directly following the grant. The report also lists 53,616 common shares held by his spouse as of September 30, 2026.
HELP completed its legal name change from Cybin Inc. to Helus Pharma Inc., effective October 1, 2026, after shareholder approval on September 22, 2026. Its common shares continue to trade under the HELP ticker, and existing shareholders need take no action; outstanding share certificates and DRS statements remain valid.
The company describes itself as clinical-stage, with HLP003 in Phase 3 clinical development for adjunctive treatment of major depressive disorder and HLP004 in Phase 2 for generalized anxiety disorder.
Cybin Inc. (HELP) Chief Financial Officer Greg Cavers reported an indirect purchase of 3,000 common shares held by his spouse on September 29, 2026, at C$18.3157 per share (US$12.9100 using an exchange rate of C$1.4188 = US$1.00). No Rule 10b5-1 plan is reported. Cavers reported 125,937 common shares held directly following the transaction.
CYBIN INC. (HELP) reports that Chief Financial Officer Greg Cavers held 125,937 common shares directly and 66,668 unvested restricted stock units as of September 29, 2026. The RSUs are from a 100,000-unit grant made October 1, 2025; each represents a contingent right to receive one common share.
CYBIN INC. (HELP) Chief Growth Officer Paul Glavine received a grant of 248,000 restricted stock units on September 30, 2026. The units vested immediately, and each represents a right to receive one common share. His reported direct holdings after the grant were 4,750,191 shares. Those holdings include shares transferred from the PLG Family Trust that were previously reported as indirect holdings; the footnote gives that amount as 230,941 shares, reduced to 230,939 due to rounding.
Cybin Inc. (HELP) changed its legal name to Helus Pharma Inc. effective October 1, 2026, after shareholders approved the change on September 22, 2026. Its common shares continue to trade on Nasdaq Global Market and Cboe Canada under HELP. The company says HLP003 is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, while HLP004 is in Phase 2 for generalized anxiety disorder.
Cybin Inc. (HELP) said shareholders approved changing its legal name to Helus Pharma Inc., effective October 1, 2026. The name-change resolution received 46,134,602 votes in favor, or 99.315% of votes cast. Shareholders also approved setting the board at eight directors, with 46,139,333 votes in favor, or 99.326%.
At the September 22, 2026 meeting, 107 shareholders represented 46,452,598 common shares, equal to 63.58% of issued and outstanding common shares as of the meeting’s record date. Theresa Firestone, Grant Froese, Paul Glavine, Michael Halstead, Eric Hoskins, Mark Lawson, Freda Lewis-Hall and Eric So were elected as directors for the ensuing year or until successors are elected or appointed. Zeifmans LLP was appointed auditor until the next annual meeting.
Cybin Inc. (operating as Helus Pharma) reports that Chief Executive Officer Michael Halstead will participate in a webcast fireside chat at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026 at 9:00 a.m. EDT. The event will be available live online with a replay on Helus Pharma’s investor relations website.
Helus Pharma is described as a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs) aimed at improving treatment for depression, anxiety and other mental health conditions. The company is advancing HLP003, a Phase 3 NSA for adjunctive treatment of major depressive disorder with U.S. FDA Breakthrough Therapy Designation, and HLP004, a Phase 2 NSA for generalized anxiety disorder, alongside a broader NSA research portfolio across Canada, the United States, the United Kingdom and Ireland.
CYBIN INC. (HELP) reported that Chief Executive Officer Michael Halstead purchased 100,000 Common Shares on September 21, 2026. The weighted average purchase price was $13.4705 per share, with individual trades executed between $13.395 and $13.53. After these open-market purchases, he directly owns 168,568 Common Shares.